Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Clearwater, FL, USA.
Department of Health Sciences, Marieb College of Health & Human Services, Florida Gulf Coast University, Fort Myers, FL, USA.
Hum Vaccin Immunother. 2022 Dec 31;18(1):2002083. doi: 10.1080/21645515.2021.2002083. Epub 2022 Feb 7.
The novel coronavirus outbreak was declared a pandemic in March 2020. We are reviewing the COVID-19 vaccines authorized for use in the United States by discussing the mechanisms of action, administration, side effects, and efficacy of vaccines developed by Pfizer, Moderna, and Johnson & Johnson. Pfizer and Moderna developed mRNA vaccines, encoding the spike protein of SARS-CoV-2, whereas Johnson & Johnson developed an adenovirus vector-based vaccine. Safety has been shown in a large cohort of participants in clinical trials as well as the general population since emergency approval of vaccine administration in the US. Clinical trial results showed the Pfizer and Moderna vaccines to be 95.0%, and the Johnson & Johnson vaccine to be 66.0% effective in protecting against moderate and symptomatic SARS-CoV-2 infection. It is important to keep medical literature updated with the ongoing trials of these vaccinations, especially as they are tested among different age groups and upon the emergence of novel variants of the SARS-CoV-2 coronavirus.
2020 年 3 月,新型冠状病毒疫情被宣布为大流行。我们正在通过讨论辉瑞、莫德纳和强生公司开发的疫苗的作用机制、管理、副作用和疗效,来审查美国批准使用的 COVID-19 疫苗。辉瑞和莫德纳公司开发了编码 SARS-CoV-2 刺突蛋白的 mRNA 疫苗,而强生公司开发了一种基于腺病毒载体的疫苗。自美国紧急批准疫苗接种以来,大量临床试验参与者和普通人群的安全性已得到证实。临床试验结果显示,辉瑞和莫德纳疫苗对预防中度和有症状的 SARS-CoV-2 感染的有效率分别为 95.0%和 66.0%,强生疫苗为 66.0%。随着这些疫苗在不同年龄组中的测试以及 SARS-CoV-2 冠状病毒新型变体的出现,及时更新医学文献以跟踪这些疫苗的临床试验非常重要。
Hum Vaccin Immunother. 2022-12-31
MMWR Morb Mortal Wkly Rep. 2021-8-27
Front Public Health. 2022
Microbiol Spectr. 2021-9-3
Clin Rheumatol. 2025-7-3
Emerg Infect Dis. 2022-7
N Engl J Med. 2021-10-7
N Engl J Med. 2021-8-12